The biomedicine and health sector is in a good place right now, as we explain on the page about Catalonia on this website, as it already has an innovative ecosystem, with solid projects and global recognition. Nevertheless, biotech companies need new funding to see results from their research and license candidates to the pharmaceutical industry to manufacture drugs and for these to reach patients. Now is when the return on investment gets interesting.
Foreign investment in Catalonia rose 35% in 2014. According to consultancy firm EY, Barcelona is one of the top 10 most attractive cities in Europe for investing and the European capital with the most jobs created from foreign investment.
Apart from private funding, Catalonia will receive investment of 868.4 million euros through 2020 from the European Regional Development Fund (ERDF), including the Smart Specialisation Strategy RIS3CAT, which is 68.1% more than the amount received under the 7th Framework Programme (2007-2013).
18 September 2018
The company Ability Pharma, member of CataloniaBio & HealthTech, has just launched a round of investment of one million euros via the crowdfunding platform Capital Cell in order to continue development of a drug that eliminates cancerous cells.
The goal of the project is to turn cancer, the second leading cause of death in the world, into a chronic illness and thus forestall the death of cancer sufferers. The drug ABTL0812 is administered in combination with chemotherapy in order to augment the response to treatment, and afterward it is administered by itself to prevent relapses.
"We want to give small ...
7 September 2018
Mimetis Biomaterials, a bone regeneration company member of CataloniaBio & HealthTech, has initiated an investment round of 2 million euros which will be raised in two phases. It is hoped to secure around 120,000 euros in the seed capital round through crowdfunding and the rest through a Series A round.
The materials manufactured by Mimetis, a company based in the Vallès Technology Park, facilitate the biological processes that regenerate the lost bone of the patient and can be applied in the dental, craniomaxillofacial and orthopaedic fields. Mimetis’ greatest achievement, however, has been 3D-printed custom implants.
The company previously closed ...
23 July 2018
German multinational corporation Hartmann, a CataloniaBio & HealthTech member, will invest €10 million between 2019 and 2021 in its two plants in Mataró and Montornès del Vallès (Barcelona), according to financial newspaper Expansión.
The Mataró factory is a global benchmark in developing and manufacturing adhesive healthcare products and is currently responsible for production of the company’s popular plasters.
In 2017, Hartmann acquired the Lindor brand from Procter & Gamble and saw revenue of €175 million in Spain, up 52% from 2016. The company is open to new acquisitions to continue growing in Spain and expects to see sales of €250 ...
3 July 2018
Banc Sabadell ha obert la nova convocatòria BStartup Health per donar suport a projectes que es trobin en fases inicials de l'àmbit de la salut (dispositius mèdics, salut digital, diagnòstic i terapèutic). Els tres projectes seleccionats rebran 75.000 euros d’inversió i un pla d’acompanyament.
El comitè cientificotècnic està format per Carlos Gallardo, CEO de CG Health Partners i membre del consell d’Almirall; Damià Tormo, soci de Columbus Venture Partners, i Montserrat Vendrell, sòcia d’Alta Life Sciences i membre de la junta de CataloniaBio & HealthTech. A més d'aquest comitè, els projectes se seleccionaran amb el suport de ...
26 June 2018
Bio€quity Europe, the longest investor event for the European biotechnology sector, will take place in Barcelona for the first time on 20th and 21st May 2019. The conference will be held in Barcelona at the initiative of the Host Regional Committee, which brings together Biocat, Ysios Capital, ACCIÓ and CataloniaBio & HealthTech.
Bio€quity Europe —organised by BioCentury and EBD Group— has showcased more than 800 leading European companies and thousands of investment and pharma business development professionals. More than 550 delegates from 26 nations attended latest edition in Ghent.
"Barcelona has all of the key ingredients for a ...
19 June 2018
FreeOx Biotech, spin-out of Hospital Clinic Barcelona-IDIBAPS and member of CataloniaBio & HealthTech, has opened a round of investment hoping to raise €500,000. The company’s goal this year is to accelerate development and the regulatory process for its drug candidate Ox-01, which has completed phase IIb, and begin preclinical trials with Ox-02. Both drugs are being used to treat stroke and other diseases of the central nervous system (CNS).
“We’re looking for a total of €500,000 and we’ve already raised €200,000 from two private investors,” explained Carlos Lurigados, co-founder and CEO of FreeOx. These investors ...
15 June 2018
The Genesis Ventures investment fund, managed by Genesis Biomed consultancy, has made its first investment of €75,000 in the NeuroHeal research project at the Institut de Neurociències (INc) at the Autonomous University of Barcelona (UAB), led by Dr Caty Casas. The agreement will allow them to accelerate development of the product and move towards creating a new spin-off.
NeuroHeal is a new first line of treatment to accelerate neuroregeneration and reduce muscle atrophy.
Genesis Ventures, which was first presented at the Barcelona Science Park in November 2017, is committed to projects in the very early stages to help them ...
12 June 2018
Catalan biomedical companies attracted €102 million in investment in 2017, with €3.4 million per operation, on average. This will allow them to push forward in the development of drugs and innovative medical technology, as reflected in the Study on investment in the Biomedical industry in Catalonia: Achievements and future challenges presented today by CataloniaBio & HealthTech and EY in Barcelona. The event drew a crowd of more than 60 entrepreneurs, investors and professionals from the sector.
Venture capital continues to be the main source of funding for companies that develop products (33%), while service firms tend to opt for ...
5 June 2018
Venture capital firm Inveready, a CataloniaBio & HealthTech member, is putting the finishing touches on a €25-million fund to invest in start-ups in the health and biotechnology arena. The fund will be launched in the coming weeks, according to information from Expansión.
With this third vehicle coming soon, to be called Biotech III, Inveready will manage more than €175 million in investment. In total, they hope to build a portfolio of 20 to 25 companies, mainly in Spain.
Photo: Sara Secall and Roger Piqué at the Inveready headquarters in Barcelona - © Expansión, Elena Ramón
1 June 2018
Banco Sabadell and Asabys Partners, founded by Josep Lluís Sanfeliu and Clara Campàs —member of the last Board of directors at CataloniaBio (2014-2018)—, have created a new venture capital fund of 60 million euros which will centre its investment activity in the health arena.
The new fund is known as Sabadell Asabys Health Innovation Fund. It will carry out initial investments in biotech, MedTech and digital health companies in Spain, as well as the UK and Israel.
The fund could obtain up to 6 million euros per company, and expects to work closely with research centres and benchmark ...